AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05743218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electropuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.
Study NCT05743218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electropuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.
Study NCT05743218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electropuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.
Study NCT06441552 — intervention group
Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional
Study NCT04712656 — intervention group
Intervention type: DEVICE
Intervention: CPAP therapy
Description: CPAP treatment of obstructive sleep apnea.
Study NCT04649125 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose escalation
Description: single fraction dose escalation to the tumour
Study NCT04649125 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: dose escalation
Description: single fraction dose escalation to the tumour
Study NCT05087953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Head-Up Tilt table test
Description: Autonomic response assessment in the orthostatic head up tilt test.
Study NCT05087953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability
Description: Assessment of heart rate variability on 24-hour Holter monitoring..
Study NCT06061172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gp-multitool.de
Description: The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~1. preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. activities (including a. activities and participation, and b. social support);~3. treatment (including a. problems with medication, and b. treatment burden);~4. complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool.
Study NCT05812092 — intervention group
Intervention type: DEVICE
Intervention: CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System
Description: CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
Study NCT04826926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Non Surgical Periodontal Therapy
Description: Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
Study NCT06050083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis audio recordings
Description: Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
Study NCT06050083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis audio recordings
Description: Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
Study NCT05259397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07225570
Description: PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
Study NCT05259397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
Study NCT04591964 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: mobile application M-Cardio based on android
Description: Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service.
Study NCT04803591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid will be administered as an injectable solution (500mg/5ml or 1000mg/10ml).
Study NCT05264103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton for gait rehabilitation (Atalante)
Description: Subjects will walk with different levels of assistance given by the robot.
Study NCT05418686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.
Description: * Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~* A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~* Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~* Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~* In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~* Additional blood (5ml) and urine (2ml) samples for colchicine determination.
Study NCT06127940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.
Study NCT06127940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temporary Stopping
Description: Temporary stop of sotorasib during SBRT
Study NCT05750342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product Caqui
Description: Supplement extracted from persimmon
Study NCT05750342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product placebo
Description: Product with identical characteristics to the experimental product.
Study NCT05494281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block with local anesthetic
Description: A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered.
Study NCT05494281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block with saline solution
Description: A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution
Study NCT05844865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)
Description: Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
Study NCT05598606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Injection
Description: 1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
Study NCT05598606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
Study NCT05172518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane plus Intermittent Capecitabine
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study NCT05172518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone plus Intermittent Capecitabine
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study NCT05172518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane plus Metronomic Capecitabine
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study NCT05172518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone plus Metronomic Capecitabine
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study NCT05172557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Program
Description: Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
Study NCT05172557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Coaching
Description: Wellness coaching sessions throughout 12 months of study participation
Study NCT06094335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality rehabilitation
Description: Children in this group received Virtual Reality Rehabilitation plus traditional physical therapy
Study NCT06094335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
Study NCT06094335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
Study NCT05279534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days
Study NCT05279534 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
Study NCT04938765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring
Study NCT04938765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 20 ml of normal saline bolus will be administered to the control group over 10 mins.
Study NCT04996537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-video digiral learning
Description: On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
Study NCT04996537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-video digiral learning
Description: On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
Study NCT06545110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib Oral Tablet
Description: Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
Study NCT06545110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baricitinib Oral Tablet
Description: Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
Study NCT06171503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: letter of invitation on MI in PMTCT service
Description: A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
Study NCT06281626 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study NCT06214598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
Study NCT06214598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AI diet
Description: diet rich in whole grains, healthy oils and polyphenols,
Study NCT06214598 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caps with standard diet
Study NCT06497712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Before the beginning of stitches, the patient will be offered a hypnotic induction. The hypnotic induction is the initial phase of the hypnosis process. Its goal is to bring the patient to a state of dissociation: the hypnotic trance. Induction is usually achieved through progressive relaxation, sensory focusing, and a process of confusion.
Study NCT05033899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
Study NCT05373225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acetic acid shockwave phonophoresis therapy
Description: This group composed of subjects. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
Study NCT05373225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave Therapy
Description: This group composed of subjects and represented the control group who will receive shock wave therapy
Study NCT05373225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy program
Description: Exercise program:~* Standing calf-stretching exercise~* Towel stretch: stretching exercise~* Ice bottle~* Towel pickup exercise~* Marble pickups exercise~* Calf raises exercises -Static and dynamic balance exercise
Study NCT05280743 — intervention group
Intervention type: DRUG
Intervention: Oxycodone
Description: exposure to opioids after Cesarean Section
Study NCT05493098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
Study NCT05493098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham (placebo) dry needling:
Description: The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
Study NCT04922645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate 1 gram Oral Tablet
Description: Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
Study NCT04922645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care phosphate-lowering therapy
Description: Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
Study NCT06478108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRSW-MIM
Description: IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.